TEL AVIV, Israel and BETHESDA, Maryland, Jun 03, 2021
The announcement comes following the launching of a Melanoma research program in April 2021, and as the company is gearing up for submission of a pre-IND meeting package and meeting request to the US Food and Drug Administration regarding its Colorectal Cancer treatment drug candidate RCC-33.
Gabriel Yariv, Cannabics Pharmaceuticals President and COO, said: “We have successfully completed a series of preclinical experiments in our in-house research facilities and have identified promising antitumor results on Breast Cancer cell lines. Based on these encouraging results, we now plan further research aimed at developing a new drug candidate for the treatment of Breast Cancer.”
Eyal Barad Cannabics Pharmaceuticals’ Co-founder and CEO commented: “This new research project for Breast Cancer is evidence of how the company can leverage its unique expertise and experience to develop new antitumor formulas using our own drug discovery platform. This Breast Cancer research project is the third cancer treatment project we have launched after Colorectal Cancer and Melanoma, and I expect that additional projects will follow in the near future.”
Breast cancer is the most common invasive cancer in women, and it is the most commonly diagnosed type of cancer globally along with lung cancer. According to the World Health Organization, in 2020, approximately 2.3M cases of Breast Cancer were diagnosed worldwide, and some 685,000 related deaths occurred globally.
personalized and conventional medicines, which certainly opens up a variety of interesting avenues to explore going forward in the field of tailored and personalized medicine”.
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those outlined in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission including, without limitation, our latest 10-Q Report filed April 14th, 2021. We undertake no duty to update any forward-looking statement or any information contained in this press release or other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc., which are condoned by the Company, must emanate from the Company itself and bear our name as its source.
View original content:http://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-files-a-pct-patent-application-for-proprietary-cancer-treatment-formulations-301288567.html
